Spravato (esketamine) is a nasal spray used for depression and was approved by the FDA in 2019. It is specifically for treatment-resistant depression, meaning depression symptoms that have not ...

Atai Life Sciences is making incremental progress towards opening door for a first psychedelic treatment for depression. Read ...

Ketamine has been making headlines for years, from the death of actor Matthew Perry to Elon Musk's reported microdosing, to its portrayal in Hulu's "The Secret Lives of Mormon Wives." ...

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...

A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against ...

Spravato (esketamine) is a prescription nasal spray that treats depression in adults. Learn about dosage, side effects, and more.

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

In the ESCAPE-TRD study, Spravato outperformed quetiapine on the main endpoint of achieving remission at eight weeks, measured by the Montgomery-Åsberg Depression Rating Scale (MADRS), with rates ...

Atai Life Sciences’ psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study, triggering the next stage of the biotech’s planned merger with mental health company ...

Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a ...

While positive, results from a late-stage clinical trial appear to be raising questions about how useful the company’s ...

Compass Pathways’ depression drug trial meets goals but falls short of investor hopes, triggering a sharp share selloff.